Dr Reddy’s Laboratories is navigating a critical transition phase as legacy gains from gRevlimid taper off, even as the company lays the groundwork for its next multi-year growth cycle.

Dr. Reddy's Laboratories share price opened at Rs 1,326.00, peaked at Rs 1,365.95, and hit a low of Rs 1,317.40, reflecting a steady trading range.

Dr. Reddy’s Laboratories has entered into a significant collaboration with Gilead Sciences to manufacture and commercialize the HIV drug Lenacapavir in India and 120 other countries.

Market expert Kushal Gupta has suggested three BUY Calls and one SELL Call for today’s trading session. Indian markets are expected to open flat today and we expect a range-bound session.

Market expert Chandan Taparia from Motilal Oswal Financial Services has suggested two BUY Calls and no SELL Call for short term traders.

Market expert Mitesh Thakkar has suggested two BUY Calls and two SELL Calls for today’s trade.